Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance

February 2019

Author(s): Merat SJ, Bru C, van de Berg D, Molenkamp R, Tarr AW, Koekkoek S, et al

Details: J Hepatol. 2019

NIHR Acknowledged: Yes